John Wingard

Summary

Affiliation: University of Florida
Country: USA

Publications

  1. ncbi Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation
    John R Wingard
    Department of Medicine, Blood and Marrow Transplant Program, Division of Hematology Oncology, University of Florida Shands Cancer Center, Gainesville, FL 32610, USA
    Clin Infect Dis 39:S176-80. 2004
  2. ncbi Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever
    John R Wingard
    Division of Hematology and Oncology, College of Medicine, University of Florida Shands Cancer Center, Gainesville, Florida 32610 0277, USA
    Am J Health Syst Pharm 64:637-43. 2007
  3. ncbi Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis
    J R Wingard
    University of Florida College of Medicine, Department of Medicine, Division of Hematology Oncology, Gainesville, FL 32610 0277, USA
    Clin Infect Dis 29:1402-7. 1999
  4. ncbi Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics
    John R Wingard
    Division of Hematology Oncology, University of Florida College of Medicine, P O Box 103633, 1376 Mowry Road, Gainesville, FL 32610 3633, USA
    Crit Rev Oncol Hematol 72:144-54. 2009
  5. ncbi Prophylaxis, empirical therapy, or pre-emptive therapy of fungal infections in immunocompromised patients: which is better for whom?
    Helen L Leather
    Department of Pharmacy, College of Medicine, University of Florida, Gainesville, Florida, USA
    Curr Opin Infect Dis 15:369-75. 2002
  6. ncbi Changes in causes of death over time after treatment for invasive aspergillosis
    John R Wingard
    Department of Medicine, University of Florida College of Medicine, Gainesville, Florida 32610 3633, USA
    Cancer 112:2309-12. 2008
  7. ncbi Influenza: preparedness for an inevitable "Emergency" for oncology and BMT units
    John R Wingard
    Division of Hematology Oncology, University of Florida College of Medicine, Gainesville, FL 32610 3633, USA
    J Natl Compr Canc Netw 6:215-22. 2008
  8. ncbi New approaches to invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patients
    John R Wingard
    Blood and Marrow Transplant Program, Division of Hematology Oncology, University of Florida Shands Cancer Center, 1376 Mowry Road, Room 145, Gainesville, FL 32610 3633, USA
    Best Pract Res Clin Haematol 20:99-107. 2007
  9. ncbi Preparing for the unthinkable: emergency preparedness for the hematopoietic cell transplant program
    John R Wingard
    University of Florida College of Medicine, Gainesville, FL 32610 0277, USA
    Biol Blood Marrow Transplant 12:1229-38. 2006
  10. ncbi Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis
    John R Wingard
    University of Florida College of Medicine, Gainesville, 32610, USA
    Clin Ther 27:960-9. 2005

Research Grants

  1. QUALITY OF LIFE AND RELATIONSHIPS AFTER BMT
    John Wingard; Fiscal Year: 2001
  2. Core Clinical Center for BMT Clinical Research Network
    John Wingard; Fiscal Year: 2007

Detail Information

Publications85

  1. ncbi Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation
    John R Wingard
    Department of Medicine, Blood and Marrow Transplant Program, Division of Hematology Oncology, University of Florida Shands Cancer Center, Gainesville, FL 32610, USA
    Clin Infect Dis 39:S176-80. 2004
    ..About 15% of patients become infected, with a case fatality rate of approximately 65%. To date, no effective prophylactic strategies have been developed...
  2. ncbi Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever
    John R Wingard
    Division of Hematology and Oncology, College of Medicine, University of Florida Shands Cancer Center, Gainesville, Florida 32610 0277, USA
    Am J Health Syst Pharm 64:637-43. 2007
    ..An analysis was conducted that evaluated and compared the cost differences between caspofungin and liposomal amphotericin B when the medications were used as empirical antifungal therapy for persistent fever during neutropenia...
  3. ncbi Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis
    J R Wingard
    University of Florida College of Medicine, Department of Medicine, Division of Hematology Oncology, Gainesville, FL 32610 0277, USA
    Clin Infect Dis 29:1402-7. 1999
    ..46; P=.002). These data indicate that elevated creatinine levels during amphotericin B treatment are associated with a substantial risk for hemodialysis and a higher mortality rate, but the risks vary in different patient groups...
  4. ncbi Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics
    John R Wingard
    Division of Hematology Oncology, University of Florida College of Medicine, P O Box 103633, 1376 Mowry Road, Gainesville, FL 32610 3633, USA
    Crit Rev Oncol Hematol 72:144-54. 2009
    ..Each type of prophylaxis has advantages and disadvantages. Additional studies are needed to optimize how these are employed in clinical practice...
  5. ncbi Prophylaxis, empirical therapy, or pre-emptive therapy of fungal infections in immunocompromised patients: which is better for whom?
    Helen L Leather
    Department of Pharmacy, College of Medicine, University of Florida, Gainesville, Florida, USA
    Curr Opin Infect Dis 15:369-75. 2002
    ..Validations of the various techniques show promise and are reviewed in this paper...
  6. ncbi Changes in causes of death over time after treatment for invasive aspergillosis
    John R Wingard
    Department of Medicine, University of Florida College of Medicine, Gainesville, Florida 32610 3633, USA
    Cancer 112:2309-12. 2008
    ..Assessment of response to invasive aspergillosis (IA) therapy has been challenging in treatment trials...
  7. ncbi Influenza: preparedness for an inevitable "Emergency" for oncology and BMT units
    John R Wingard
    Division of Hematology Oncology, University of Florida College of Medicine, Gainesville, FL 32610 3633, USA
    J Natl Compr Canc Netw 6:215-22. 2008
    ..Ongoing engagement by the entire team to evaluate the effectiveness of its actions and modify its plan as necessary will ensure success...
  8. ncbi New approaches to invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patients
    John R Wingard
    Blood and Marrow Transplant Program, Division of Hematology Oncology, University of Florida Shands Cancer Center, 1376 Mowry Road, Room 145, Gainesville, FL 32610 3633, USA
    Best Pract Res Clin Haematol 20:99-107. 2007
    ..Combining the new diagnostic tools with new drugs, novel strategies are being evaluated to change our approaches to these deadly infections...
  9. ncbi Preparing for the unthinkable: emergency preparedness for the hematopoietic cell transplant program
    John R Wingard
    University of Florida College of Medicine, Gainesville, FL 32610 0277, USA
    Biol Blood Marrow Transplant 12:1229-38. 2006
    ..This report provides the framework for a HCT-specific emergency preparedness plan that can be used by individual centers to develop customized guidelines on preparing for, responding to, and recovering from an emergency...
  10. ncbi Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis
    John R Wingard
    University of Florida College of Medicine, Gainesville, 32610, USA
    Clin Ther 27:960-9. 2005
    ..7% and 62.8% of patients, respectively) and exhibited a generally better safety profile, particularly with respect to impaired renal function (IRF) (P = 0.02)...
  11. ncbi The changing face of invasive fungal infections in hematopoietic cell transplant recipients
    John R Wingard
    Department of Medicine, University of Florida Shands Cancer Center, Division of Hematology Oncology, Gainesville, Florida 32610 0277, USA
    Curr Opin Oncol 17:89-92. 2005
    ....
  12. ncbi A new era of antifungal therapy
    John R Wingard
    Blood and Marrow Transplant Program, Division of Hematology Oncology, University of Florida Shands Cancer Center, Gainesville, USA
    Biol Blood Marrow Transplant 10:73-90. 2004
    ..It is hoped that these new therapies and new diagnostics will usher in a new era of antifungal therapy...
  13. ncbi Antifungal chemoprophylaxis after blood and marrow transplantation
    John R Wingard
    Division of Hematology Oncology, University of Florida College of Medicine, Gainesville, FL 32610, USA
    Clin Infect Dis 34:1386-90. 2002
    ..Fluconazole prophylaxis is highly effective for the control of invasive yeast infections and associated with few breakthrough infections. The development of antimould prophylaxis in this patient population is a high priority...
  14. ncbi Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation
    John R Wingard
    University of Florida, Gainesville, FL, USA
    Blood 116:5111-8. 2010
    ..This trial was registered at www.clinicaltrials.gov as NCT00075803...
  15. ncbi Empirical antifungal therapy in treating febrile neutropenic patients
    John R Wingard
    Department of Medicine, Blood and Marrow Transplant Program, University of Florida Shands Cancer Center, Gainesville, Florisa 32610 0277, USA
    Clin Infect Dis 39:S38-43. 2004
    ..Newer diagnostic tools are needed to target those most in need of antifungal therapy...
  16. ncbi A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group
    J R Wingard
    Division of Hematology, University of Florida College of Medicine, Gainesville, FL 32610 0277, USA
    Clin Infect Dis 31:1155-63. 2000
    ..9% and 12.3% vs. 32.1%; P=.004). After day 1, infusional reactions were less frequent with ABLC, but chills/rigors were still higher (21.0% and 24.3% vs. 50.7%; P<.001). Therapeutic success was similar in all 3 groups...
  17. ncbi Empiric antifungal therapy for the neutropenic patient
    J R Wingard
    Bone Marrow Transplant Program, University of Florida College of Medicine, USA
    Oncology (Williston Park) 15:351-63; discussion 363-4, 367-9. 2001
    ..Finally, the future of diagnostic and therapeutic strategies for protecting the immunocompromised patient will be considered...
  18. ncbi Opportunistic infections after blood and marrow transplantation
    J R Wingard
    Bone Marrow Transplant Program, University of Florida College of Medicine, Gainesville, Florida 32610, USA
    Transpl Infect Dis 1:3-20. 1999
    ..Such shifts and new syndromes pose continuing new challenges to the transplant clinician...
  19. ncbi Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital
    W B Grow
    University of Florida College of Medicine, Shands Hospital, Gainesville, FL 32610-0277, USA
    Bone Marrow Transplant 29:15-9. 2002
    ..These data have important implications in an era of alternate donor transplants and more intense immunosuppression. Established strategies implementing newer, less toxic antifungal agents as prophylaxis in high-risk patients are needed...
  20. ncbi Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts
    Claudio G Brunstein
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA
    Blood 118:282-8. 2011
    ..The trials are registered at www.clinicaltrials.gov under NCT00864227 (BMT CTN 0604) and NCT00849147 (BMT CTN 0603)...
  21. ncbi Granulocytic sarcoma (chloroma) of the breast: a diagnostic dilemma and review of the literature
    Barbara Shea
    Division of Hematology Oncology, Department of Medicine, University of Florida, Gainesville, Florida 32610, USA
    Breast J 10:48-53. 2004
    ..It appears that early initiation of systemic acute myelogenous leukemia (AML)-type chemotherapy is beneficial and may delay or avert the development of AML in bone marrow and blood...
  22. ncbi Engraftment syndrome in breast cancer patients after stem cell transplantation is associated with poor long-term survival
    S A Khan
    Division of Hematology Oncology, College of Medicine, University of Florida, Gainesville 32610 0277, USA
    Biol Blood Marrow Transplant 7:433-8. 2001
    ..Thus, patients with ES should be considered for close follow-up and further therapy posttransplantation...
  23. ncbi Subcutaneous phaeohyphomycosis in transplant recipients: review of the literature and demonstration of in vitro synergy between antifungal agents
    C J Clancy
    Department of Medicine, University of Florida College of Medicine, Gainesville 32610, USA
    Med Mycol 38:169-75. 2000
    ..Results of in vitro testing of the isolate for susceptibility to a combination of amphotericin B, flucytosine and itraconazole confirmed the potential role of combination antifungal therapy in the setting of refractory infection...
  24. ncbi Strongyloides stercoralis hyperinfection in hematopoietic stem cell transplantation
    B Wirk
    Bone Marrow Transplant Program, Division of Hematology Oncology, University of Florida College of Medicine, Gainesville, Florida 32610, USA
    Transpl Infect Dis 11:143-8. 2009
    ....
  25. ncbi Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study
    Hong Liu
    Department of Medicine, University of Florida, Gainesville, FL, USA
    Leuk Lymphoma 49:306-14. 2008
    ..11 months, P = 0.004). In conclusion, the detection of a significant population of APC by FCM prior to ASCT significantly correlates with poorer PFS in MM patients...
  26. ncbi GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation
    M S Zumberg
    University of Florida College of Medicine, Department of Medicine and the Bone Marrow Transplant Program, Shands Hospital at the University of Florida, Gainesville, USA
    Cytotherapy 4:531-8. 2002
    ..Resource utilization for fever treatment and evaluation may be greater with GM-CSF. Determination of which agent is more cost-effective depends on institutional acquisition costs...
  27. ncbi Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis
    J R Wingard
    University of Florida, Gainesville, Florida, USA
    Transpl Infect Dis 9:182-8. 2007
    ..Voriconazole, a broad-spectrum triazole, has demonstrated significantly improved survival compared with conventional amphotericin B (CAB) as initial therapy for invasive aspergillosis (IA)...
  28. ncbi A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation
    D J Winston
    Department of Medicine, UCLA Center for the Health Sciences, Los Angeles, CA 90095, USA
    Bone Marrow Transplant 28:187-96. 2001
    ..These results should be considered when designing cost-effective strategies for the use of intravenous immunoglobulin in allogeneic marrow transplants receiving other current regimens for prophylaxis of GVHD and infection...
  29. ncbi Infections following hematopoietic stem cell transplantation
    H L Leather
    Department of Pharmacy, Shands at the University of Florida, College of Pharmacy, Gainesville, Florida, USA
    Infect Dis Clin North Am 15:483-520. 2001
    ..As we increase our understanding of the HSCT process, and use the immune system rather than relying on high-dose chemotherapy, the authors are likely to reduce toxicities and improve patient outcomes...
  30. ncbi Gastroparesis following bone marrow transplantation
    D A Eagle
    University of Florida College of Medicine, Gainesville, FL 32610-0277, USA
    Bone Marrow Transplant 28:59-62. 2001
    ..Patients usually respond to prokinetic drugs at the time of scintigraphy. GVHD and CMV infection do not appear to be major contributing factors...
  31. ncbi Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients
    B A Collin
    Department of Medicine, University of Florida, Gainesville, FL 32610, USA
    Clin Infect Dis 33:947-53. 2001
    ..aeruginosa and the Enterobacter, Serratia, Citrobacter group. There was no mortality attributable to gram-positive organisms such as Staphylococcus aureus and viridans streptococci...
  32. ncbi Monitoring vital signs in a bone marrow transplant unit: are they needed in the middle of the night?
    S Sharda
    University of Florida College of Medicine, Department of Pediatrics, Gainesville, FL, USA
    Bone Marrow Transplant 27:1197-200. 2001
    ..0002). There was also a trend for CNS events (P = 0.057) to be associated with MON intervention. Larger, prospective studies need to be done to accurately identify day time risk factors that can predict the need for night time monitoring...
  33. ncbi Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT
    C Cable
    Division of Hematology Oncology, Department of Medicine, University of Florida, Gainesville, FL, USA
    Bone Marrow Transplant 45:31-7. 2010
    ..Yet, rapid attainment of full donor chimerism after flu/TBI is associated with greater survival than after flu/ATG/BU. Further, larger prospective randomized studies are required to define the advantage of one regimen over the other...
  34. ncbi Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab
    S Skoda-Smith
    Department of Pediatrics, University of Florida College of Medicine, Gainesville 32610-0296, USA
    Bone Marrow Transplant 27:329-32. 2001
    ..The administration of Rituximab in the early post-transplant course may provide additional anti-tumor activity without affecting the new stem cell compartment...
  35. ncbi Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation
    L N Gordan
    Department of Medicine, Division of Hematology-Oncology, College of Medicine, University of Florida, P.O. Box 100277, Gainesville, FL 32610, USA
    Leuk Lymphoma 44:815-20. 2003
    ....
  36. ncbi Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study
    Borje S Andersson
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston 77005, USA
    Biol Blood Marrow Transplant 8:145-54. 2002
    ..In conclusion, the IV Bu in this regimen was very well tolerated and demonstrated excellent antitumor efficacy, most likely because of dose assurance with predictable pharmacokinetics...
  37. ncbi A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger
    Marc S Zumberg
    University of Florida College of Medicine, Department of Medicine, Gainesville 32610, USA
    Biol Blood Marrow Transplant 8:569-76. 2002
    ..In conclusion, a platelet transfusion trigger of 10K was found to be safe; however, a decrease in platelet use was not achieved because of safety measures incorporated into our study design...
  38. ncbi Use of bronchoalveolar lavage to detect galactomannan for diagnosis of pulmonary aspergillosis among nonimmunocompromised hosts
    M Hong Nguyen
    Department of Medicine, University of Florida College of Medicine, Gainesville, Florida 32610, USA
    J Clin Microbiol 45:2787-92. 2007
    ..Given the likelihood of false-positive results, a BAL GM test should not be ordered routinely in this population...
  39. ncbi Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients
    Cornelius J Clancy
    Department of Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA
    J Clin Microbiol 45:1759-65. 2007
    ..9% and 62.5%, respectively (cutoff, > or = 1.0). In conclusion, BAL GM testing facilitated more-rapid diagnoses of IPA and the institution of antifungal therapy among non-lung solid-organ transplant recipients and helped to rule out IPA...
  40. ncbi Late effects of cancer and hematopoietic stem-cell transplantation on spouses or partners compared with survivors and survivor-matched controls
    Michelle M Bishop
    Department of Medicine, University of Florida College of Medicine, Gainesville, FL 32610 0277, USA
    J Clin Oncol 25:1403-11. 2007
    ..The purpose of this study was to examine the health-related quality of life and post-traumatic growth (PTG) of spouses/partners compared with survivors and controls and to identify factors associated with those outcomes...
  41. ncbi Spatial distribution of blood vessels and CD34+ hematopoietic stem and progenitor cells within the marrow cavities of human cancellous bone
    Christopher J Watchman
    Department of Radiation Oncology, University of Arizona, Tucson, Arizona, USA
    J Nucl Med 48:645-54. 2007
    ..The objective of the present study was to directly measure the spatial concentration of these cells, as well as marrow vasculature structures, within images of human disease-free bone marrow...
  42. ncbi Access to stem cell transplantation: do women fare as well as men?
    Paulette Mehta
    Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL, USA
    Am J Hematol 72:99-102. 2003
    ..While boys with ALL appear to receive SCT at a higher rate, this difference is likely attributable to biological rather than social reasons...
  43. ncbi Umbilical cord blood produces small megakaryocytes after transplantation
    Mark Ignatz
    Department of Pediatrics, University of Florida, Gainesville, Florida, USA
    Biol Blood Marrow Transplant 13:145-50. 2007
    ..For the first time, we demonstrate that the attainment of adult size in CB-derived megakaryocytes is delayed after human CB transplantation...
  44. ncbi Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy
    William W Hope
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 195:455-66. 2007
    ..Little is known about the pathogenesis of invasive pulmonary aspergillosis and the relationship between the kinetics of diagnostic markers and the outcome of antifungal therapy...
  45. ncbi Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts
    Brahm H Segal
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Clin Infect Dis 44:402-9. 2007
    ..Finally, we discuss the implications of newer antifungal agents and diagnostic adjuncts in the design of future clinical trials to evaluate prophylaxis and early prevention strategies...
  46. ncbi The role of the donor in the repair of the marrow vascular niche following hematopoietic stem cell transplant
    William B Slayton
    University of Florida Program in Stem Cell Biology and Regenerative Medicine, Department of Pediatrics, University of Florida Health Science Center, Gainesville, Florida 32610, USA
    Stem Cells 25:2945-55. 2007
    ..Donor support for the repair of the marrow vascular niche may be a critical first step of hematopoietic engraftment...
  47. ncbi Sites and kinetics of donor thrombopoiesis following transplantation of whole bone marrow and progenitor subsets
    Xiao Miao Li
    Department of Pediatrics, University of Florida, Gainesville, USA
    Exp Hematol 35:1567-79. 2007
    ..The spleen is a site of hematopoiesis in a healthy mouse, and hematopoietic activity increases in response to stress. We hypothesized that the spleen is a major site of early post-transplant thrombopoiesis...
  48. ncbi Increased risk of lethal graft-versus-host disease-like syndrome after transplantation into NOD/SCID mice of human mobilized peripheral blood stem cells, as compared to bone marrow or cord blood
    Norbert Claude Gorin
    Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD 21231, USA
    J Hematother Stem Cell Res 11:277-92. 2002
    ..Quantitative criteria for optimal T cell content of allogeneic donor hematopoietic grafts from different sources are discussed...
  49. ncbi An assay for long-term engrafting human hematopoietic cells based on newborn NOD/SCID/beta2-microglobulin(null) mice
    Fumihiko Ishikawa
    Department of Veterans Affairs Medical Center, Medical University of South Carolina, Charleston, SC 29401-5799, USA
    Exp Hematol 30:488-94. 2002
    ..5 +/- 0.42% at 2 months after secondary transplantation. CONCLUSION: Our assay may provide a quantitative method for analysis of human hematopoietic stem cells...
  50. ncbi A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients
    Raleigh Bowden
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Clin Infect Dis 35:359-66. 2002
    ..However, infusion-related chills and fever occurred more frequently in patients receiving ABCD than in those receiving AmB...
  51. ncbi Bone marrow sinusoidal endothelial cells undergo nonapoptotic cell death and are replaced by proliferating sinusoidal cells in situ to maintain the vascular niche following lethal irradiation
    Xiao Miao Li
    Department of Pediatrics, University of Florida, Gainesville, FL 32610, USA
    Exp Hematol 36:1143-1156. 2008
    ..Bone marrow sinusoids remain predominantly host-derived following bone marrow transplantation. Systematic analysis was conducted at the cellular level to investigate how the host sinusoidal structures survived after lethal irradiation...
  52. ncbi Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival
    Mary Eapen
    Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
    Biol Blood Marrow Transplant 13:1461-8. 2007
    ..The higher rate of cGVHD after PBSC transplants and, consequently, more frequent late adverse events warrant extended follow up of PBSC recipients...
  53. ncbi Transplanted human cord blood cells generate amylase-producing pancreatic acinar cells in engrafted mice
    Hitoshi Minamiguchi
    Department of Veterans Affairs Medical Center and Department of Medicine, Medical University of South Carolina, Charleston, SC, USA
    Pancreas 36:e30-5. 2008
    ..Based on this developmental proximity between liver and pancreatic acinar cells, we examined whether human cord blood (CB) cells can generate pancreatic cells in vivo using a murine xenograft model...
  54. ncbi Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
    Raoul Herbrecht
    Département d Hématologie et d Oncologie, Hopital de Hautepierre, Strasbourg, France
    N Engl J Med 347:408-15. 2002
    ..Voriconazole is a broad-spectrum triazole that is active against aspergillus species. We conducted a randomized trial to compare voriconazole with amphotericin B for primary therapy of invasive aspergillosis...
  55. ncbi Racial and ethnic composition of volunteer cord blood donors: comparison with volunteer unrelated marrow donors
    Karen K Ballen
    American Red Cross Cord Blood Program, University of Massachusetts Memorial Health Care, Worcester, MA, USA
    Transfusion 42:1279-84. 2002
    ..Umbilical cord blood is an alternative peripheral blood progenitor cell source for patients who need transplantation. A presumed advantage of cord blood is the ability to increase minority recruitment...
  56. ncbi An assay for human hematopoietic stem cells based on transplantation into nonobese diabetic recombination activating gene-null perforin-null mice
    Hitoshi Minamiguchi
    Department of Veterans Affairs Medical Center, Medical University of South Carolina, Charleston, South Carolina 29401-5799, USA
    Biol Blood Marrow Transplant 11:487-94. 2005
    ..Accordingly, conditioned newborn NOD- Rag1 null Prf1 null mice provide a desirable model for an assay of long-term transplantable human HSCs...
  57. ncbi Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America
    Thomas J Walsh
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
    Clin Infect Dis 46:327-60. 2008
  58. ncbi Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign
    Reginald E Greene
    Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Infect Dis 44:373-9. 2007
    ....
  59. ncbi Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma
    Christopher R Cogle
    University of Florida, Division of Hematology/Oncology, Gainesville, Florida 32610, USA
    Am J Hematol 73:169-75. 2003
    ....
  60. ncbi Factors associated with parameters of engraftment potential of umbilical cord blood
    Thomas J George
    University of Florida, College of Medicine, Gainesville, Florida, USA
    Transfusion 46:1803-12. 2006
    ..A total of 1033 UCB samples with neonatal and paternal characteristics that might influence hematopoietic content were examined...
  61. ncbi Hepatotoxicity associated with antifungal therapy after bone marrow transplantation
    John R Wingard
    Clin Infect Dis 41:308-10. 2005
  62. ncbi Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies
    Michael Boeckh
    University of Washington, Seattle, WA 81009, USA
    Biol Blood Marrow Transplant 9:543-58. 2003
    ....
  63. ncbi Study of renal safety in amphotericin B lipid complex-treated patients
    Barbara D Alexander
    Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Infect Dis 40:S414-21. 2005
    ..These data provide evidence that ABLC may be used safely to treat patients who are at increased risk for renal impairment...
  64. ncbi Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit
    Borje S Andersson
    Biol Blood Marrow Transplant 9:722-4. 2003
  65. ncbi Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation
    Michael A Andrykowski
    Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, KY 40536 0086, USA
    J Clin Oncol 23:599-608. 2005
    ..To examine health-related quality of life (HRQOL) and growth, and spiritual well-being in adult survivors of hematopoietic stem-cell transplantation (HSCT) for a malignant disease...
  66. ncbi Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease
    Vijay Reddy
    Division of Hematology Oncology, University of Florida College of Medicine, 1600 SW Archer Rd, Gainesville, FL 32610, USA
    Blood 103:4330-5. 2004
    ..Low numbers of circulating DCs significantly increase the risk for relapse and acute GVHD and predict death after allogeneic SCT...
  67. ncbi The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: introduction and overview
    John H Rex
    AstraZeneca Pharmaceuticals, Macclesfield, United Kingdom
    Clin Infect Dis 39:S165-9. 2004
    ..This supplement presents 12 articles by leading clinicians who are currently active in trials in this area and presents a current view of the unmet needs and challenges...
  68. ncbi Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies
    Casey B Williams
    Blood and Marrow Transplant Program of the Kansas City Cancer Centers, Cancer Institute at Saint Luke s Hospital, Kansas City, Missouri, USA
    Biol Blood Marrow Transplant 10:614-23. 2004
    ..On the basis of the dosing guidelines and schedule outlined in this study, our data suggest that administration of IV Bu 3.2 mg/kg IV every 24 hours for 4 doses in combination with Cy may result in excessive toxicity...
  69. ncbi A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy
    Francis J Giles
    M D Anderson Cancer Center, Department of Leukemia, The University of Texas, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 28:559-65. 2004
    ..A major impact of Iseganan on reducing stomatitis, UOM, or its clinical sequelae in patients receiving stomatotoxic therapy was not detected on this study...
  70. ncbi Bone marrow transdifferentiation in brain after transplantation: a retrospective study
    Christopher R Cogle
    Program in Stem Cell Biology and Regenerative Medicine, University of Florida Shands Cancer Center, Gainesville, FL 32610, USA
    Lancet 363:1432-7. 2004
    ..Transplantable human haemopoietic cells could serve as a therapeutic source for long-term regenerative neuropoiesis...
  71. ncbi A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial)
    Francis J Giles
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA
    Leuk Lymphoma 44:1165-72. 2003
    ..6 and 2.0 (P = 0.0131). Iseganan was well tolerated; no systemic absorption was detected. Iseganan is safe and may be effective in reducing UOM and its clinical sequelae...
  72. ncbi Increased levels of tumor necrosis factor alpha are associated with an increased risk of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation
    Vijay Reddy
    University of Florida College of Medicine, Gainesville, FL 32610, USA
    Biol Blood Marrow Transplant 11:698-705. 2005
    ..017). In conclusion, a high posttransplantation TNF level is significantly associated with the risk for developing CMV infection. Early detection of high levels of TNF may be used to identify patients at high risk for developing CMV-Ag...
  73. ncbi Developmental differences in megakaryocyte maturation are determined by the microenvironment
    William B Slayton
    University of Florida Department of Pediatrics, Gainesville, Florida 32610, USA
    Stem Cells 23:1400-8. 2005
    ..These differences may contribute to the delay in platelet engraftment that frequently complicates cord blood transplants...
  74. ncbi Is combination antifungal therapy for invasive aspergillosis a necessity in hematopoietic stem-cell transplant recipients?
    Helen L Leather
    Shands Healthcare at the University of Florida, 32610 0316, USA
    Curr Opin Infect Dis 19:371-9. 2006
    ..The recent literature is reviewed and the relative arguments for and against combination antifungal therapy are outlined with summative recommendations to assist practitioners in decision-making...
  75. ncbi New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies
    Helen L Leather
    Shands at the University of Florida, Gainesville, FL 32610 0316, USA
    Blood Rev 20:267-87. 2006
    ....
  76. ncbi Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients
    Helen Leather
    Shands at the University of Florida, Gainesville, Florida 32610 0316, USA
    Biol Blood Marrow Transplant 12:325-34. 2006
    ....
  77. ncbi Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Res
    J Douglas Rizzo
    Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    Biol Blood Marrow Transplant 12:138-51. 2006
    ....
  78. ncbi Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    Vijay Reddy
    Division of Hematology Oncology, College of Medicine, University of Florida, Gainesville, Florida 32610, USA
    Biol Blood Marrow Transplant 11:1014-21. 2005
    ..Patients with high pretransplantation IL-12 levels have an increased likelihood of higher posttransplantation IL-12 levels, possibly because of a host-graft interaction, and this may predispose to better clinical outcomes...
  79. ncbi National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
    Alexandra H Filipovich
    Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229, USA
    Biol Blood Marrow Transplant 11:945-56. 2005
    ..It is currently recommended that systemic therapy be considered for patients who meet criteria for chronic GVHD of moderate to severe global severity...
  80. ncbi Treatment of zygomycosis with posaconazole in a patient with acute myeloid leukemia
    Helen L Leather
    University of Florida, Gainesville, 32610, USA
    Clin Adv Hematol Oncol 3:773-7. 2005
  81. ncbi Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome
    Thomas F Patterson
    Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 3900, USA
    Clin Infect Dis 41:1448-52. 2005
    ..In that trial, treatment with voriconazole or amphotericin B deoxycholate could be followed with other licensed antifungal therapies (OLAT). Here, we report the impact of OLAT on the outcome of patients with invasive aspergillosis...
  82. ncbi Typhlitis with concurrent appendicitis in a patient with chronic lymphocytic leukemia
    Christopher R Cogle
    University of Florida Shands Cancer Center, Gainesville, FL 32610, USA
    Clin Adv Hematol Oncol 1:284-6; discussion 286. 2003
  83. ncbi Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation
    Stephanie J Lee
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 104:2194-200. 2004
    ....
  84. ncbi Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt
    Elias J Anaissie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Clin Infect Dis 43:1031-9. 2006
  85. ncbi Learning from our failures: the antifungal treatment conundrum
    John R Wingard
    Clin Infect Dis 46:1434-5. 2008

Research Grants5

  1. QUALITY OF LIFE AND RELATIONSHIPS AFTER BMT
    John Wingard; Fiscal Year: 2001
    ..This information is essential to subsequent planning and implementation of relevant, well-aimed interventions to minimize psychosocial disruption and enhance growth in future BMT recipients and their loved ones. ..
  2. Core Clinical Center for BMT Clinical Research Network
    John Wingard; Fiscal Year: 2007
    ..End of abstract.) ..